The Healthy and At-Risk Populations Program currently has 26 members, 12 of whom are new to the cancer center. The new members include a number of senior and junior recruits to UCLA, as well as previously unaffiliated UCLA faculty members. A new senior level recruit is Lenore Arab, Ph.D., whose focus is on nutrition and cancer. The JCCC provided critical support for Dr. Arab's research. In addition, we were fortunate that the School of Nursing recently recruited Felicia Hodge, Dr.PH, who is also Director, Center for American Indian/Indigenous Research and Education (CAIRE) on the UCLA campus. Dr. Hodge has a long history of tobacco control and cancer screening research in native American populations and has been an excellent addition to HARP. Also in the past funding cycle, Robert Kaplan, Ph.D., was recruited to be the Chair of Health Services in the School of Public Health, and he has joined HARP. Dr. Kaplan is an internationally renowned scholar in the areas of health services and health psychology and conducts research in broad content areas including tobacco control, cancer screening, quality of life, and quality of care. Other internal senior level faculty who have been attracted to join HARP during the past funding cycle include Lillian Gelberg, M.D., Family Medicine and Leeka Kheifets, Ph.D., Epidemiology. Junior faculty recruited to UCLA during the past cycle who have newly joined the cancer center include Michael Ong, M.D., Ph.D., General Internal Medicine-Health Services and Dominic Frosch, Ph.D., General Internal Medicine-Health Services Research. The Program is extremely dynamic, and is viewed as a welcoming and supportive environment for collaborative research. Our members have national and international reputations, and we have in our program three members of the Institute of Medicine. The total number of publications in the last cycle was 425 out of which 18% were inter-programmatic and 18% were intra-programmatic indicating a high level of collaborative research in the program. Fourteen percent of the publications could be characterized as high impact. During the current funding year, peerreviewed funding totaled $11.4 million in total costs, including $5.3 million from the National Cancer Institute. As with other Program Areas, JCCC fosters a number of interactive activities and many of the Shared Resources that support investigators in the HARP Program Area. During the current grant cycle, funds from the JCCC in the form of CCSG Developmental Funds, institutional support and philanthropic gifts to the HARP Program Area total $348,500. These funds supported Seed Grants, the annual Helene Brown award and trainees. Four of the Program Area Members were the recipients of JCCC support.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Los Angeles
Los Angeles
United States
Zip Code
Li, Gang; Lu, Xuyang (2015) A Bayesian approach for instrumental variable analysis with censored time-to-event outcome. Stat Med 34:664-84
Epeldegui, Marta; Blom, Bianca; Uittenbogaart, Christel H (2015) BST2/Tetherin is constitutively expressed on human thymocytes with the phenotype and function of Treg cells. Eur J Immunol 45:728-37
Bower, Julienne E; Crosswell, Alexandra D; Stanton, Annette L et al. (2015) Mindfulness meditation for younger breast cancer survivors: a randomized controlled trial. Cancer 121:1231-40
Arensman, Michael D; Telesca, Donatello; Lay, Anna R et al. (2014) The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth. Mol Cancer Ther 13:2303-14
Li, Keyu; Tavaré, Richard; Zettlitz, Kirstin A et al. (2014) Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments. Mol Cancer Ther 13:2607-17
Ke, Ruian; Loverdo, Claude; Qi, Hangfei et al. (2014) Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration. J Antimicrob Chemother 69:724-7
Fu, Maoyong; Maresh, Erin L; Helguera, Gustavo F et al. (2014) Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer. Mol Cancer Ther 13:902-15
Leoh, Lai Sum; Morizono, Kouki; Kershaw, Kathleen M et al. (2014) Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter. J Gene Med 16:11-27
Tong, Maomeng; McHardy, Ian; Ruegger, Paul et al. (2014) Reprograming of gut microbiome energy metabolism by the FUT2 Crohn's disease risk polymorphism. ISME J 8:2193-206
De Azambuja, Katherine; Barman, Provabati; Toyama, Joy et al. (2014) Validation of an HPV16-mediated carcinogenesis mouse model. In Vivo 28:761-7

Showing the most recent 10 out of 192 publications